An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2015
At a glance
- Drugs CNF 2024 (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Pharmacodynamics
- Sponsors Biogen Idec
- 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 02 May 2009 Additional trial centre/investigator Keedy, Vicki reported by Vanderbilt-Ingram Cancer Center.